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ABSTRACT 
The murine peptidylarginine deiminase (PAD) has 
five isoforms encoded by different genes and partici- 
pates in a variety of cellular functions through the 
citrullination of target proteins. The crystal structure 
of human PAD4 with a dimeric form was previously 
solved because of the enzyme’s relevance to rheuma- 
toid arthritis. PAD6, abundant in mouse oocytes and 
eggs, is believed to take part in early events of 
embryogenesis, but its biochemical properties are 
little understood. Here we have purified and charac- 
terized a recombinant PAD6. A PAD6 cDNA was 
cloned from mouse ovary RNA and expressed in 
Escherichia coli through pET29 and pGEX vectors. 
When benzoyl-L-arginine ethyl ester was used as a 
substrate, no appreciable activity was detected with a 
cell homogenate under conditions where a human 
PAD4 cDNA caused significant activity. Both pro- 
teins were affinity-purified to near homogeneity. The 
circular dichroism spectra of PAD6 and human 
PAD4 were similar in the far ultraviolet region. On 
molecular sieving, PAD6 was eluted faster than 
human PAD4. The cross-linking of PAD6 with dime- 
thyl suberimidate clearly showed six bands on an 
sodium dodecyl sulfate-polyacrylamide gel. These 
results indicate that PAD6 can constitute a hexameric 
structure. The purified PAD6 still showed no enzy- 
matic activity. This unique structure and loss in 
enzymatic activity is strongly suggested to favor the 
formation of egg cytoplasmic sheets as the architectu- 
ral protein. 
Keywords: Peptidylarginine Deiminase; Isoform; Dimer; 
Hexamer; Mouse Oocytes; Cytoplasmic Sheets 
1. INTRODUCTION 
Peptidylarginine deiminases (PAD) (protein-arginine dei- 
minase; E.C. 3.5.3.15) are an enzyme that catalyzes the 
removal of the imino-moiety of peptidylarginine to yield 
peptidylcitrulline and ammonia in the presence of Ca2+. 
PADs have been demonstrated to play a variety of roles 
in cell signaling pathways, apoptosis, differentiation and 
transcriptional regulation. Dysregulation of PAD activity 
is considered to be responsible for various diseases such 
as rheumatoid arthritis (RA), cancer and colitis. Therefore, 
development of agents regulating the PAD activity is 
required for reducing the disease severity [1]. 
In humans and rodents, the enzyme has five isoforms 
differing in distribution: PAD1, epidermis and uterus; 
PAD2, various tissues; PAD3, hair follicles; PAD4, 
blood cells; PAD6, egg and ovary (for reviews see, e.g., 
[2-4]). The genes for these PADs are clustered on chro- 
mosome 4 at D3 in mice and on chromosome 1 at p36.13 
in humans [5,6], and PADs share 40% - 55% sequence 
homology. PAD4 has been studied extensively in rela- 
tion to the pathogenesis of RA, because PAD4 gene 
expression is prominent in the synovial tissue of RA 
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patients, and levels of an anti-cyclic citrullinated peptide 
antibody (anti-CCP antibody) are significantly augmented 
in their sera [7]. Therefore, the anti-CCP antibody has 
recently become a diagnostic marker of RA. Moreover, 
Suzuki et al. [8] found that mutations of the PAD4 gene 
are closely linked to RA in an SNP analysis. For these 
reasons, the crystal structure of human PAD4 (hPAD4) 
has been solved [9]. hPAD4 has a dimeric structure with 
a head-to-tail shape whose N- and C-terminal regions 
function in Ca2+-binding and catalysis, respectively. The 
binding of Ca2+ to an apo-hPAD4 induces a gross con- 
formational change resulting in a catalytically active 
form. Cys645 near the C-terminal is necessary for cata- 
lysis. However, only one PAD occurs in prokaryotes [10]; 
the Porphyromonas gingivalis PAD also carries a rea- 
ctive Cys residue that acts as a nucleophile essential for 
catalysis despite no requirement of Ca2+ [11,12]. 
In contrast to PAD1 to 4, the biochemical properties 
of PAD6 are poorly understood. Interestingly, the crys- 
tallographic data on PAD4 along with a sequence align- 
ment among five PADs imply that the acidic residues 
involved in Ca2+-binding and a reactive Cys in the C- 
terminal region are not conserved in PAD6 [9]. These 
findings provide the possibility that PAD6 lacks enzy- 
matic activity. To learn more about structure-function 
relationships among PADs, it is necessary to purify and 
characterize PAD6. Since the crystal structure of hPAD4 
is available, and hPAD4 and mouse PAD4 have high 
amino acid sequence homology, we have compared the 
properties of PAD6 and hPAD4, and present data for a 
unique structure of PAD6. 
2. MATERIALS AND METHODS 
2.1. Materials 
The biochemical reagents and materials used were ob- 
tained as follows: murine reverse transcriptase, Takara 
Bio (Kyoto, Japan); KOD+ DNA polymerase, Toyobo 
(Shiga, Japan); Sephacryl S300, Ni2+ Sepharose, Pre- 
ScissionTM endoprotease, GE Health care; pET28 and 
pET29, Novagen/Merck; Luria-Bertani (LB) broth, Ter- 
rific broth (TB), dimethyl suberimidate, Nacalai tesque 
(Kyoto, Japan); DE52, Whatman (NJ, USA) and the 
Amicon UltraTM spin column (cut-off Mr ~ 10,000), Mil- 
lipore (MA, USA). Other materials were also obtained 
commercially and used without further treatment. 
2.2. cDNA Cloning 
cDNA cloning and the construction of expression vec- 
tors were performed using general PCR-based proce- 
dures as described previously [13]. Total RNA was iso- 
lated from mouse ovaries. cDNA to PAD6 was synthe- 
sized with random hexamer/oligo(dT) primers by reverse 
transcriptase. An aliquot of the cDNA library was ampli- 
fied by KOD+ DNA polymerase with custom-made 
primers in a thermal cycler (ABI 2720) (Figure 1(a)). 
The reaction profile was 30 cycles of denaturing at 94˚C 
for 30 sec, annealing at 55˚C for 30 sec, and elongation 
at 68˚C for 2 min. The product, once treated with phe- 
nol/chloroform, was digested with restriction endonu- 
cleases and ligated to a pET29 or pGEX6 vector precut 
with the corresponding restriction enzymes. These DNAs 
were used to transform E. coli BL21 (DE3) or BL21, and 
antibiotic-resistant colonies were subjected to DNA se- 
quencing in a Hitachi-ABI sequencer 3100. 
2.3. Purification of PAD6 
Proteins were purified at 0˚C - 4˚C. Herein, 10 mM 
Tris-HCl (pH 8.0) is referred to as “Tris”, unless other- 
wise stated. A one-fiftieth volume of overnight culture of 
E. coli harboring pET29/PAD6 cDNA (Figure 1(b)) was 
inoculated into a 2L-flask containing 500 ml of TB/ 
kanamycin, and shaken at 37˚C (95 shuttles/min) until 
the cell density reached 0.7 (absorbance at 600 nm). 
Then, isopropyl 1-thio-β-D-galactoside (IPTG) was ad- 
ded to make a concentration of 0.15 mM, and the culture 
was continued at 25˚C overnight. The cells collected by 
centrifugation were stored in four 50-ml tubes at –80˚C 
until used. The thawed cells were suspended in 20 ml of 
Tris, 1 mM EDTA, lysozyme (5 mg), 10 mM 2-mer- 
captoethanol and 1mM phenylmethylsulfonyl fluoride, 
and frozen again at –80˚C for 30 min. The thawed sam- 
ple was sonicated at 200-W at three intervals over a pe- 
riod of 1 min. After centrifugation at 12,000 X g for 15 
min, the supernatant was diluted 2-fold with Tris, and  
 
Figure 1. Primers and vectors used. (A) Forward (F) and re-
verse (R) primer sets, a, b, c, were used for the amplification of 
PAD6 cDNA from a mouse ovary cDNA library. The PCR 
products were cleaved with NdeI + XhoI, NdeI + NotI, or 
BamHI + NotI restriction endonucleases, and introduced into a 
pET29, pET28, or pGEX vector previously cut with the corre-
sponding endonucleases. 
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applied to a DE52 column (2-cm diameter X 4-cm 
height) prewashed with Tris containing 1 mM EDTA and 
10 mM 2-mercaptoethanol (Buffer A). After a wash with 
60 ml of Buffer A, PAD6 was eluted with 90 ml of Tris 
containing 5 mM mercaptoethanol and 0.2 M NaCl 
(Buffer B). The eluent was adjusted to make 0.5 M NaCl 
and 20 mM imidazole. To this solution in 50-ml tubes 
was added 5 ml of Ni2+ Sepharose (50% v/v). The mix- 
ture was added was gently rotated for 1 h, and centri- 
fuged at 1000 X g for 2 min. The precipitate was washed 
five times with Tris containing 0.5 M NaCl and 20 mM 
imidazole. Finally, PAD6 was released by adding tritu-
rated imidazole to make 0.3 M. The eluent concen- 
trated on a spin column was applied to a Sephacryl S300 
column (1.5 cm × 98 cm) prewashed with Buffer B, and 
5-ml portions were collected. The purity of each fraction 
was checked by sodium dodecyl sulfate (SDS) poly- 
acrylamide gel electrophoresis (PAGE), concentrated by 
a spin column again and kept in aliquots at –80˚C. Al- 
ternatively, Ni2+ Sepharose chromatography was pre- 
ceded by gel chromatography; a DE52-eluted prepara- 
tion was concentrated with 70% ammonium sulfate and 
applied to the Sephacryl column. Each fraction (5 ml) 
was purified by the Ni2+ Sepharose treatment as above. 
2.4. Purification of hPAD4 and PAD6 Derived 
from pGEX6 
hPAD4 and PAD6 were obtained through the vector 
pGEX6 (Figure 1(b)). E. coli cells harboring pGEX6/ 
hPAD4 or PAD6 were cultured overnight in TB supple- 
mented with ampicillin and IPTG as described above. 
The cell homogenate was spun, and the supernatant was 
applied to a DE52 column equilibrated with Tris. The 
column was extensively washed with Tris containing 
0.15 M NaCl and 10 mM 2-mercaptoethanol. The wash- 
out solution was brought to a concentration of 0.5 M 
with respect to NaCl. This preparation received 5 ml of 
GST-Sepharose (50% v/v), and was gently mixed by 
rotation for 2 h. The gels were washed 5 times with Tris 
containing 5 mM 2-mercaptoehanol and 0.5 M NaCl, 
and then the 10-ml suspension received 30 µl of Pre- 
Scission protease. The digestion was continued for 24 h 
with slow rotation. The supernatant after centrifugation 
was further concentrated on a spin column and applied 
to the Sephacryl S300 column. Aliquots of the 5-ml frac- 
tion were subjected to SDS-PAGE and active fractions 
were used for experiments. 
2.5. Chemical Cross-Linking Experiment 
The chemical cross-linking experiment was carried out 
as described by Davies and Stark [14]. The reaction mix- 
ture (20 µl) consisted of 0.1 M triethanolamine-HCl (pH 
8.5), 2 - 5 µg of protein, and a 10- to 30-fold excess of 
dimethyl suberimidate-HCl. The reaction was allowed to 
proceed for 2 h at 20˚C, and stopped by adding an equal 
volume of 2% SDS, 20 mM sodium phosphate (pH 7.2), 
5% 2-mercaptoethanol, 0.05% bromophenol blue and 
50% glycerol. After being denatured at 95˚C for 2 min, 
the samples were subjected to 3.5% SDS-polyacryla- 
mide disc gel electrophoresis at 8 mA/disc, and stained 
with Coomassie Brilliant Blue. 
2.6. Enzyme Assay 
PAD activity was measured in a 700-µl volume with 
benzoyl-L-arginine ethyl ester (BAEE) as the substrate 
as described previously [15], in which 10 mM dithio- 
threitol was included. After incubation at 37˚C for an 
appropriate period, the reaction was terminated by add- 
ing 100 µl of 8 N perchloric acid. Citrulline in the 333- 
µl supernatant was reacted with 417 µl of 2.25 M 
H3PO4/4.5 M H2SO4, 167 µl of 20 mM diacetyl mon- 
oximine, and 43 µl each of 30 mM thiosemicarbazide 
and NH4Fe(SO4)2 at 99˚C for 22 min. The absorbance of 
the reactant was recorded at 540 nm. The molar extinc- 
tion coefficient for citrulline was 5 × 104. One unit of 
activity was defined as the amount of enzyme catalyz- 
ing the formation of 1 µmol of product per min. 
2.7. Other Methods 
Circular dichroism (CD) spectra of purified proteins 
were recorded in a JASCO J-805 as described previously 
[13]. Prior to analysis, the samples were dialyzed against 
10 mM potassium phosphate (pH 7.2) and 0.2 M NaCl 
for 15 h. Protein was measured by the Lowry method 
using bovine serum albumin (BSA) as a standard [16]. 
Site-directed mutagenesis of PAD4 was performed as 
described [13]. 
3. RESULTS 
3.1. Expression of PAD6 cDNA  
A PAD6 cDNA was cloned from mouse ovary RNA, 
ligated to a pET29 expression vector, and expressed in E. 
coli in the presence of IPTG. For the PAD enzyme assay, 
BAEE was used as a substrate throughout the experi- 
ment. As shown in Figure 2, the cell homogenate of 
hPAD4 showed time- and dose-dependent activity, whereas 
that of PAD6 did not. The latter result verifies a predict- 
tion by X-ray analysis that PAD6 may not bear enzy- 
matic activity [9]. 
3.2. Purification of PAD6 
PAD6 protein was purified to near homogeneity from the 
supernatant of the E. coli homogenate, because an in- 
tense band of PAD6 with a Mr of 76,777 was not seen in 
the insoluble fraction upon SDS-PAGE. A single band of 
protein was recovered from the SDS gel and assigned as 
PAD6 by peptide sequencing (Figure 3). Ser2 was found  
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Figure 2. hPAD4 and PAD6 activity in cell homogenates. (A) 
The time course of PAD activity was determined colorimetri-
cally with 50 ml of cell homogenate (~ 20 mg/ml) as described 
in Materials and Methods. Open and closed circles denote the 
activity of the hPAD4 and PAD6 homogenates, respectively. (B) 
Concentration-dependence of the hPAD4 (○) and PAD6 (●) 
activity of the cell homogenates. The reaction time was 30 min. 
The acid soluble fraction (333-ml) of the reaction mixture was 
subjected to color development and measured at 540 nm (the 
ordinate absorbance). 
to be the N-terminal residue instead of the translation 
initiator Met. The yield of PAD6 was extremely low (be- 
low 0.5 mg from 1L-cutured cells), whereas that of 
hPAD4 exceeded 3 mg. Since hPAD4 was isolated from 
a GST-fused polypeptide by cleavage with PreScission 
protease, the N-terminal GST segment might be useful 
for translation efficiency, and/or protein stability. To test 
this possibility, PAD6 was expressed through pGEX 
(Figure 1(b)). However, the yield of PAD6 was still com-
parable to, or less than, that through pET29. A pET28 
vector having a long N-terminal tag (20 residues) was 
also without effect (Figure 1), suggesting that the C- 
terminal His tag does not interfere with the expression.  
 
Figure 3. Elution profiles of PAD6 and hPAD4 obtained by 
Sephacryl S300 gel chromatography. (Upper panel) An ammo-
nium sulfate-enriched preparation (~50 mg) of an eluent from a 
DE52 column was applied to a Sephacryl S300 column, and 
fraction numbers 30 to 39 were subjected to Ni2+ Sepharose 
chromatography as described in Materials and Methods. Ali-
quots of the imidazole-eluted samples were analyzed by 8% 
SDS-PAGE. (Lower panel) An hPAD4 preparation (~5 mg) 
released through PreScission protease digestion was applied to 
a Sephacryl S300 column, and aliquots of the eluent were ana-
lyzed by 8% SDS-PAGE. Separately, authentic standards were 
run to locate the elution position as monitored at 280 nm: LDH, 
lactate dehydrogenase; BSA, bovine serum albumin; OVA, 
ovalbumin. 
Therefore, the secondary structure of a local nucleotide 
sequence in the PAD6 mRNA may impede translation, or 
the codon usage of the PAD6 mRNA may be inadequate 
in prokaryotic cells. 
3.3. Elution Profile of PAD6 on Sephacryl S300 
PAD6 and hPAD4 were subjected to molecular sieving, 
and each fraction was visualized by staining after SDS- 
PAGE (Figure 3). PAD6 appeared with a broad peak at 
Mr ~ 200,000, while hPAD4 was recovered much slower 
than PAD6. A major band of hPAD was seen around the 
position of BSA, which differed from the expected elu- 
tion position of about Mr 150,000 (dimer) [9]. 
3.4. Chemical Cross-Linking 
The results of size-exclusion chromatography were 
slightly ambiguous. Thus, we estimated the quaternary 
structure based on results of chemical cross-linking ex- 
periments. RNase A, creatine kinase, lactate dehydro- 
genase and glutamate dehydrogenase were used as a 
monomer or oligomeric proteins. The protein bands were 
visualized by staining after disc SDS-PAGE. Unex- 
pectedly, PAD6 revealed six bands (Figure 4). hPAD4 
produced a dimer although its population was slightly 
small compared with a parent band. PAD6 via pGEX 
also showed a hexamer (data not shown). These results, 
together with those of the molecular sieving experiment, 
imply that hPAD4 constitutes in part a monomeric 
population under the present conditions, and PAD6 can 
form a hexamer (calculated Mr ~ 456,000) despite that  
 
Figure 4. Chemical cross-linking of PAD6 and hPAD4 with 
dimethyl suberimidate. Chemical cross-linking experiments were 
carried out as described in Materials and Methods. RNase A 
(Mr 14,000), creatine kinase (CK, subunit Mr 41,000), lactate 
dehydrogenase (LDH, subunit Mr 35,000), and bovine gluta-
mate dehydrogenase (GLDH, subunit Mr 52,000) were used as 
standards. The gel concentration was 3.5% except for RNase A 
(8%) and CK (6%). 
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little PAD6 was seen at the elution position of apoferri- 
tin (calculated Mr 443,000). The shape of PAD6 is con- 
sidered to be different from that of apoferritin. 
3.5. CD Spectra 
CD spectra of PAD6 and hPAD4 were measured in the 
far ultraviolet region (Figure 5). Their patterns seemed 
to be similar; the α-helix content was calculated to be 
26.0% and 27.2% for hPAD4 and PAD6, respectively, 
from the [θ]obs value based on the equation of Chen and 
Yang [17]. The CD spectrum of mouse PAD2 indicated 
an α-helix content of 29.1% [18]. An X-ray analysis 
revealed that hPAD4 is comprised of 22.4% α-helix and 
39.1% β-strand [9]. It is conceivable that PAD6 and 
hPAD4 have a similar secondary structure. 
3.6. Enzymatic Activity of Purified Preparations 
The specific activity of purified hPAD4 was 1.2 µmol/ 
mg/min, whereas purified PAD6 exhibited no detectable 
activity even with 50 µg and 15-h incubation. hPAD4 
Cys645 is essential for catalysis because a Cys645Ala 
mutant did not show activity [9]. We also confirmed the 
Cys645Ala mutant to be enzymatically inactive. In PAD6, 
the corresponding residue is Ala664. It is of interest whe- 
ther an Ala664Cys protein has activity. The mutant, how- 
ever, did not exhibit enzymatic activity, indicating that 
there exist critical residues other than Ala664. 
4. DISCUSSION 
The structure of mammalian eggs is fortified with 
cytoplasmic sheets. An Mr ~ 69,000 protein, occurring in 
relatively high abundance in eggs, was found to associate 
with the fibrous network of intermediate filaments [19]. 
Wright et al. separated this soluble protein by two- 
dimensional gel electrophoresis, identified it as an iso- 
form of PAD by mass spectrometry, and named it ePAD  
 
Figure 5. CD spectral profiles of PAD6 and hPAD4. About 0.3 
mg/ml each of PAD6 and hPAD4 were recorded in the far ul-
traviolet region. The measurement conditions were: cell, 10- 
mm light path; response, 2 sec; band width, 1 nm, scan speed, 
20 nm/min. 
[20]. An ortholog was found in humans, and ePAD was 
renamed PAD6 [6]. Esposito et al. [21] created PAD6- 
null mice lacking cytoplasmic sheets and female fertility, 
and showed an absence of positive signals in these 
animals when ovarian sections were stained with an anti- 
H4Cit3 antibody. They concluded that this was due to 
the lack of PAD6 activity. On the other hand, an X-ray 
analysis of hPAD4 along with a sequence alignment of 
PADs suggested that enzymatic activity may not be 
inherent to PAD6 [9]. In the present study, we first 
showed that the purified PAD6 does not exhibit enzyma- 
tic activity when BAEE is used as a substrate. A micro- 
bial PAD occurs in P. gingivalis whose primary sequence 
differs greatly from that of PAD6 [22]. Rodriguez et al. 
[11,12] showed with purified a monomeric P. gingivalis 
PAD that Cys351 acts as a nucleophile in catalysis and no 
Ca2+ cofactor is required. These results suggest that a 
particular Cys residue in the active site is a prerequisite 
for deimination, but Ca2+ is not necessarily required in 
the microbial enzyme. Our preliminary finding that an 
Ala664Cys mutant did not exhibit enzymatic activity 
shows the necessity of acidic residues for Ca2+ binding. 
Among 19 residues involved in the binding of Ca2+, 13 
are acidic. In human PAD6, 7 Glu and Asp residues are 
not conserved [9]. Human and mouse PADs are similar 
in primary structure. Accordingly, the PAD6 Ala664Cys 
mutant is expected to be incapable of binding to Ca2+. 
Whether bound Ca2+ exists in PAD6 remains to be 
determined. It is tempting to examine whether the re- 
placement of these non-acidic residues with acidic residues 
could restore the enzymatic activity. The creation of a 
chimera between hPAD4 and PAD6 may be another 
approach. 
Studies in vitro and in vivo have evoked a great 
discrepancy as to why an inactive PAD6 can function as 
an enzyme in the egg and ovary. Several possibilities 
exist: 1) a true proteinous substrate of PAD6 occurs in 
vivo; 2) an unknown protein such as a chaperone is 
needed for the activity; 3) Ca2+ is not the correct cofactor; 
and 4) the recombinant PAD6 differs from the naturally 
occurring form due to a lack of post-translational modi- 
fication. Concerning the second possibility, Snow et al. 
[23] reported the necessity of tyrosine/tryptophan mono- 
oxygenase activation protein (YWHA or 14-3-3 protein) 
for interaction with PAD6 via phosphorylation at the 
stage encompassing oocytes to early embryos. 
The principle finding of this study is that PAD6 is a 
hexamer unlike hPAD4, although the two resemble each 
other in secondary structure. This was not noted pre- 
viously. PAD6 may be in a state of equilibrium regarding 
the association-dissociation of the protomer depending 
on the protein concentration or the solvent. Under 
chemical cross-linking conditions, the PAD6 concentra- 
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tion was relatively high (about 0.5 mg/ml), whereas 
about 0.1 mg/ml of PAD6 was used for a Sephacryl S300 
chromatography, and so the protein would be gradually 
diluted during development; this may explain why PAD6 
migrated so far. Arita et al. [9] in their X-ray analysis 
queried whether the dimeric form is specific to PAD4 or 
common to all PADs although the residues involved in 
the dimerization are partially conserved. Unfortunately, 
we could not determine which residues play a role in the 
subunit-subunit interaction of hPAD4. The residues res- 
ponsible for the hexamer of PAD6 are expected to be 
different from those in the case of hPAD4. Further study 
is needed to clarify whether the unique structure of 
PAD6 favors the formation of cytoplasmic sheets in 
eggs. 
In conclusion, we have first demonstrated that PAD6 
has no enzymatic activity when BAEE is used as a sub- 
strate, and is a hexameric protein unlike other dimeric 
PADs. This unique structure is suggested to favor the 
formation of egg cytoplasmic sheets. 
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